C-Jun N-terminal kinase mediates calcitonin gene-related peptide expression in rat trigeminal ganglion in vitro | C-Jun N-Terminal Kinaz Si{dotless}çan Trigeminal Ganglionunda in Vitro Olarak Kalsitonin Gene-baǧli{dotless} Peptid Yapi{dotless}mi{dotless}ni{dotless} Düzenler

Guogang Luo,Bobo Yuan,Xingyun Yuan,Kang Huo,Wenjing Fan,Shemin Lü,Yongxiao Cao,Yaping Zhang
2012-01-01
Journal of Neurological Sciences
Abstract:Objective: Calcitonin gene-related peptide (CGRP) plays a prominent role in migraine pathophysiology. However, the underlying molecular mechanisms that are responsible for regulating CGRP expression are not fully understood. Using an in-vitro model of organ culture of rat trigeminal ganglion (TG), the present study aims to investigate the role of c-Jun N-terminal kinase (JNK) in regulation of CGRP. Methods: The TG was isolated from Sprague-Dawley (SD) rats and then organ cultured in presence of inflammatory cytokines tumor necrosis factor-alpha (TNF-α) (50μg/L) or interleukin-1β (IL-1β) (25μg/L) with and without a specific JNK inhibitor SP600125 (10-5M) or an anti-migraine drug sumatriptan (0.5g/L) for 24h. Real-time polymerase chain reaction (RT-PCR) and Western blotting were used to evaluate the CGRP-mRNA expression and phosphorylated JNK (pJNK) protein in rat TG after the organ culture. Results and Conclusions: The JNK inhibitor significantly reduced the organ culture and cytokines-induced up-regulation of CGRP-mRNA expression compared with control (P<0.05), indicating that a transcriptional mechanism was involved. Interestingly, the antimigraine drug sumatriptan had similar effect. Western blotting showed that the cytokines significantly increased pJNK protein level, while this increase could decrease by sumatriptan and SP600125 (P<0.05), demonstrating that JNK mediated the up-regulation of CGRP expression induced by the cytokines. This may suggest a novel pharmacotherapeutical target for migraine treatment.
What problem does this paper attempt to address?